Please ensure Javascript is enabled for purposes of website accessibility

Aphria Earns a New GMP Certification to Aid Its European Expansion

By Cory Renauer - Jan 21, 2020 at 10:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Canadian cannabis producer's EU operations just took a big step forward.

It's about to get a lot easier for medical marijuana patients in Europe to buy their cannabis from Aphria (APHA) by the end of the year. One of the company's subsidiaries, Avanti Rx Analytics recently earned a good manufacturing practices (GMP) certification from the Malta Medicines Authority.

Malta might be a small island nation in the Mediterranean, but the certification allows the company to ship products to any European Union member state that permits medical marijuana sales.

Enough to go around

Aphria expects to begin making shipments of medical cannabis to CC Pharma GmbH, its German subsidiary, by the end of May. It's hard to say just how much cannabis Aphria will ship to the EU in the quarters ahead, but it's probably safe to assume the Canadian producer won't have trouble meeting demand.  

Marijuana growing operation.

Image source: Getty Images.

In Canada, Aphria boasts 2.4 million square feet of operating space that can produce up to 255,000 kilograms of cannabis annually. Unfortunately, the company only reported sales of 7,062 kilograms during the three months ended Nov. 30, 2019.

Enough profits ahead?

If Aphria's EU investments don't significantly boost the company's bottom line by the end of this calendar year, its stock price has a long way to tumble.

Aphria reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) that reached 1.9 million Canadian dollars during the company's fiscal second quarter. That's better than an adjusted loss, but it's hardly enough to justify the stock's recent $1.4 billion market cap.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aphria Stock Quote
Aphria
APHA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.